Truist Securities Defending Pacira Pharmaceuticals (PCRX): 'Knee Jerk Reaction Overdone As We See Limited Path For Generic To Launch Despite Approval'
Tweet Send to a Friend
Truist Securities analyst Les Sulewski reiterated a Buy rating and $45.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
